“Changes in SPD-L1 Levels During PD-1 Inhibitor Treatment Do Not Affect Advanced NSCLC Prognosis”

https://pubmed.ncbi.nlm.nih.gov/38115995

This study found that changes in sPD-L1 levels during PD-1 inhibitor treatment do not significantly influence the prognosis of advanced NSCLC patients, regardless of gender, age, or treatment type.